Nat Commun:原发性前列腺癌整体表观遗传学分类研究

2018-12-22 AlexYang MedSci原创

雄激素受体(AR)是前列腺癌中的关键驱使转录因子,受表观遗传学的紧密调控。到目前为止,大多数表观遗传学分析都在细胞系或者有限的组织样本中进行。最近,有研究人员为了综合的研究原发性前列腺癌的表观遗传学背景,在100个前列腺癌肿瘤中对AR和组蛋白修饰标记(H3K27ac, H3K4me3, H3K27me3)进行了RNA-seq和ChIP-seq分析。研究发现,5种数据类型的整体分子亚型阐释了3种主要

雄激素受体(AR)是前列腺癌中的关键驱使转录因子,受表观遗传学的紧密调控。到目前为止,大多数表观遗传学分析都在细胞系或者有限的组织样本中进行。

最近,有研究人员为了综合的研究原发性前列腺癌的表观遗传学背景,在100个前列腺癌肿瘤中对AR和组蛋白修饰标记(H3K27ac, H3K4me3, H3K27me3)进行了RNA-seq和ChIP-seq分析。研究发现,5种数据类型的整体分子亚型阐释了3种主要的原发性前列腺癌亚型,其中2种与TMPRSS2-ERG明显相关。重要的是,他们鉴定了第3种亚型,表现为AR低的染色质结合能力和火星,但是FGF和WNT信号活性很高。虽然神经内分泌标记基因为阳性,这些肿瘤与拷贝数无关,并且突变程度低,且与腔B亚型相关的不良治疗结果基因特性显著减少。

最后,研究人员指出,他们阐释了前列腺癌中转录和表观遗传控制的一种特殊机制,表明了3种亚型中AR决定的严格基因调控的差异性。

原始出处:

Suzan Stelloo, Ekaterina Nevedomskaya, Yongsoo Kim et al. Integrative epigenetic taxonomy of primary prostate cancer. Nat Commun. 21 Nov 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087485, encodeId=4f98208e485bd, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jan 20 11:02:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883497, encodeId=a580188349e7a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 11 03:02:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846738, encodeId=80b81846e38c4, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu May 23 05:02:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357666, encodeId=59d635e666f6, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Jan 09 18:22:23 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843969, encodeId=9e4f184396956, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Aug 31 13:02:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
    2019-01-20 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087485, encodeId=4f98208e485bd, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jan 20 11:02:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883497, encodeId=a580188349e7a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 11 03:02:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846738, encodeId=80b81846e38c4, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu May 23 05:02:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357666, encodeId=59d635e666f6, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Jan 09 18:22:23 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843969, encodeId=9e4f184396956, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Aug 31 13:02:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
    2019-06-11 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087485, encodeId=4f98208e485bd, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jan 20 11:02:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883497, encodeId=a580188349e7a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 11 03:02:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846738, encodeId=80b81846e38c4, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu May 23 05:02:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357666, encodeId=59d635e666f6, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Jan 09 18:22:23 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843969, encodeId=9e4f184396956, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Aug 31 13:02:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087485, encodeId=4f98208e485bd, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jan 20 11:02:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883497, encodeId=a580188349e7a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 11 03:02:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846738, encodeId=80b81846e38c4, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu May 23 05:02:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357666, encodeId=59d635e666f6, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Jan 09 18:22:23 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843969, encodeId=9e4f184396956, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Aug 31 13:02:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
    2019-01-09 kafei

    学习了谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2087485, encodeId=4f98208e485bd, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jan 20 11:02:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883497, encodeId=a580188349e7a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 11 03:02:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846738, encodeId=80b81846e38c4, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu May 23 05:02:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357666, encodeId=59d635e666f6, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Jan 09 18:22:23 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843969, encodeId=9e4f184396956, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Aug 31 13:02:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]

相关资讯

Prostate Cancer P D:前列腺癌积极监测患者的多参数核磁共振成像作用研究

多参数核磁共振成像(mpMRI)在积极监测(AS)患者中的使用非常有前景。最近,有研究人员分析了mpMRI在AS患者中的作用。研究人员对英文文献进行了综合的搜索,文献的截止日期为2017年10月30日。在排除了重复之后,总共有226个研究被选择作为研究的对象。对这些研究进行入选标准分析后,总共有43个研究被鉴定为符合他们的系统性回顾研究,总共包括了6605名患者。研究发现,跟踪调查的AS患者的MR

Prostate Cancer P D:核磁共振成像的术前分期和前列腺癌手术阳性手术切缘风险研究

是否利用核磁共振成像(MRI)进行术前分期能够减少前列下癌阳性手术切缘的风险仍旧不清楚。最近,有研究人员评估了手术切缘的影响与术前MRI讨论中MRI呈现的骨盆神经保留程度。研究群体是一个单中心、观察性的群体,包括了2013年10月到2015年6月之间的1037名经历了机器人辅助根治性前列腺切除术的男性患者。其中,557名经历了术前MRI和术前MRI讨论,410名并没有经历上述过程。研究发现,MRI

Oncogene:Kras突变能够诱导的CD24表达上调能够增强前列腺癌的多能性和骨转移

前列腺癌(PCA)在男性中是一种最常见的恶性肿瘤之一,并且是世界范围内导致男性死亡癌症中第二大诱因。最近,有研究人员报道了具有条件LSL/KrasG12DP或者BRAFF-V600E等位基因的PCA模型且携带前列腺特异性p53功能缺失能够概括反应人类PCA前期病变、组织病理学和临床行为。研究人员发现类EMT表型和骨转移行为的发展和重新编程需要Kras激活和p53缺失的同时发生。来源于这些模型的原发

Prostate Cancer P D:前列腺切除术后复发性前列腺癌中,早期挽救性放射治疗和SRT后PAS很低值影响研究

对于那些根治性前列腺切除术(RP)后具有复发性前列腺癌的患者,挽救放射性治疗(SRT)为治疗提供了第二次机会。欧洲指南(EAU)推荐SRT在PSA<0.5ng/ml。最近,有研究人员分析了根据指南推荐的SRT的效果,并调查了SRT后PSA最低值的预测效果。研究包括了301名PSA<0.5ng/ml(均值0.192ng/ml,IQR 0.110-0.300)时经历SRT的患者,时间为19

CLIN CANCER RES:乳腺癌或前列腺癌家族史与前列腺癌风险的关系

乳腺癌和前列腺癌在家族中常常共同发生,有前列腺癌家族史的女性患乳腺癌的风险增加。前列腺癌是最有遗传可能的癌症之一,但很少有文章研究其与家族性乳腺癌的关系。CLIN CANCER RES近期发表了一篇文章,研究一级亲属中患有家族性乳腺癌或前列腺癌增加前列腺癌风险的程度。

CLIN CANCER RES:STAT3抑制联合CpG免疫激活有效治疗前列腺癌

前列腺癌对免疫治疗存在明显的耐药,部分原因是肿瘤相关髓系细胞中的致耐受性STAT3信号传导。CLIN CANCER RES近期发表了一篇文,研究STAT3抑制与Toll样受体9(TLR9)刺激相结合以激活针对前列腺癌的免疫反应的可行性。